Announcements Trials
Browse Landscape

Status

No longer available 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1Expanded_access 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Melanoma 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

veliparib 2tucatinib 2leronlimab 2abemaciclib 2Trastuzumab 2Capecitabine 2Alpelisib 2zenocutuzumab 1selpercatinib 1sacituzumab govitecan 1ribociclib 1pertuzumab 1pegilodecakin 1palbociclib 1margetuximab 1iniparib 1glembatumumab vedotin 1gedatolisib 1eribulin 1Vinorelbine 1Proton Pump Inhibitors 1Letrozole 1Lapatinib 1Hydrocortisone 1Everolimus 1Cisplatin 1Ado-Trastuzumab Emtansine 1AM0010 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × AM0010 × Breast × Clear all
NCT03554434 2020-03-02

An Expanded Access Program for AM0010 (Pegilodecakin)

Eli Lilly and Company

No longer available
BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡